Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900744 · ClinicalTrials.gov registry record
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 121
- Enrollment target
NCT00900744 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 121 participants.
The verdict
NCT00900744 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
Study Summary
The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose in patients with a genetic CYP2D6 polymorphism. The investigators also plan to investigate other genetic variations in the metabolism of tamoxifen.
Interventions
- DRUG Tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900744
The ClinicalTrials.gov registry entry for NCT00900744 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tamoxifen is the first listed.
NCT00900744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900744 about?
NCT00900744 is a clinical study titled "A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6". The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose in patients with a genetic CYP2D6 polymorphism. The investigators also plan to investigate other genetic variations in the metabolism of tamoxifen.
What is the current status of trial NCT00900744?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2009-01. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00900744?
The interventions under investigation include: Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT00900744?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.